XconomyAmicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc.CNNMoneyCRANBURY, N.J., Aug. 31, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, and Scioderm, Inc. a privately-held biopharmaceutical company focused on ...Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to PipelineTheStreet.comWith $229M Deal, Amicus Gets a New Drug And Perhaps a VoucherXconomyAmicus bags PhIII rare disease drug in $847M Scioderm buyoutFierceBiotechall 4 news articles »